The landscape of type 1 diabetes diagnosis and treatment is evolving rapidly, providing hope for early intervention and improved outcomes. Traditionally, type 1 diabetes was diagnosed at a critical stage when beta cell function was severely compromised, often in emergency settings due to diabetic ketoacidosis. However, advancements in testing and medication are shifting this paradigm. Dr. Kevan Herold discusses the latest developments in identifying and managing early stages of type 1 diabetes to delay disease progression.
Revised Classification and Growing Interest
The current classification system for type 1 diabetes recognizes the disease’s gradual onset, characterized by a continuous loss of insulin-producing beta cells. Metabolic and immunologic markers now help define three distinct stages:
Stage 1: The presence of autoantibodies with normal glucose tolerance.
Stage 2: Impaired glucose tolerance, with a 75% likelihood of progressing to stage 3 within five years.
Stage 3: Clinical type 1 diabetes, often presenting with symptoms such as diabetic ketoacidosis.
This classification has gained attention for several reasons. First, it allows for the identification of asymptomatic prediabetic patients through autoantibody and glucose tolerance testing. Second, early detection can significantly reduce the incidence of diabetic ketoacidosis. Third, treatments like teplizumab, tested in the TN10 trial, have shown promise in delaying stage 3 onset by an average of two years.
Identifying High-Risk Individuals for Early Testing
The approval of teplizumab by the FDA has expanded the criteria for testing individuals at high risk for type 1 diabetes. Previously, testing focused on those with a family history of the disease. Now, individuals with other autoimmune conditions, such as thyroid disease and celiac disease, are also considered candidates for early testing due to shared genetic factors.
Testing is recommended at a young age to maximize clinical significance. Current guidelines suggest initial testing in children around ages 2 to 3, with a follow-up around ages 5 to 7, and potentially again in adolescence due to a secondary peak in type 1 diabetes incidence.
Recommended Testing Protocols
Primary healthcare professionals can order tests for four specific autoantibodies—insulin autoantibody (IAA), glutamic acid decarboxylase autoantibody (GADA), tyrosine phosphatase autoantibody (IA2A), and zinc transporter autoantibody (ZnT8A). The presence of two or more autoantibodies indicates stage 1 type 1 diabetes. Annual monitoring with random plasma glucose and hemoglobin A1C is advised for children with positive autoantibodies.
Healthcare providers are encouraged to refer patients with positive autoantibody tests to TrialNet, a research network dedicated to the prevention and early treatment of type 1 diabetes. TrialNet collaborates closely with primary healthcare professionals to identify and manage at-risk individuals.
Delaying Disease Progression
Teplizumab, approved to delay the progression from stage 2 to stage 3, can be prescribed by primary healthcare providers or endocrinologists. Administered in outpatient settings, this medication is often covered by insurance for early-stage patients. Future availability of teplizumab for stage 3 patients is anticipated, given its demonstrated benefits even after clinical onset.
Benefits of Early Detection and Intervention
Early testing and treatment offer several advantages. Identifying at-risk individuals reduces the occurrence of diabetic ketoacidosis and minimizes exposure to high blood glucose levels, which can cause organ complications. Delaying the disease allows patients to develop better management skills and adopt lifestyle changes such as increased physical activity and healthier eating habits. Additionally, this delay provides time for further medical advancements.
For families, a negative autoantibody test in children with type 1 diabetes relatives can offer significant reassurance, with over 90% testing negative.
Ongoing Research and Future Directions
TrialNet is exploring various treatments, including anti-thymocyte globulin (ATG), and is investigating the potential of combining medications to enhance their effects. Research is also focused on using stem cells to replace beta cells and identifying individuals at risk for other autoimmune diseases to enable early intervention.
Efforts are underway to recruit diverse populations for type 1 diabetes research, ensuring that advancements benefit all communities.
In summary, early detection and intervention in type 1 diabetes are transforming patient outcomes, offering hope and tangible benefits through innovative testing and treatment strategies.
“Tour de Cure” Returns to St. Charles to Boost Diabetes Research Funding
Diabetes Accelerates Severe Health Conditions by 15-20 Years, Drastically Reducing Life Expectancy
Fathers with Type 1 Diabetes May Be More Likely to Pass on the Disease Than Mothers
